Table 2.
Summary of the economic outcomes of each study per year.
| Study | Authors, Year | Total Cost | Cost Savings | Average Cost Savings per Patient | QALY | ICER |
|---|---|---|---|---|---|---|
| ST1 | Yao et al., 2021 [36] | PA: USD 110,851.18 (EUR 94,223.50) RA: USD 111,508.01 (EUR 94,781.81) |
PA: USD 656.83 (EUR 558.31) compared to RA | PA: EUR 0.06 compared to RA | PA: 0.81 RA: 0.74 |
RA-PA: Dominated by PA |
| ST2 | Negoescu et al., 2020 [37] | PA: USD 16,585.42 (EUR 14,926.88) RA: USD 15,847.69 (EUR 14,262.92) ES: USD 15,853.68 (EUR 14,268.31) |
RA: USD 737.73 (EUR 663.96) compared to PA and USD 5.99 (EUR 5.39) compared to ES | NA | PA: 0.74 RA: 0.73 ES: 0.73 |
RA-PA: USD 146,509.12 (EUR 131,858.21) ES-RA: Dominated by RA |
| ST3 | Attar et al., 2019 [38] | PA: EUR 186,635,650 ES: EUR 201,879,000 |
PA: EUR 15,243,350 compared to ES | PA: EUR 0.76 compared to ES | NA | NA |
| ST4 | Freeman et al., 2016 [39] | PA: GBP 13,980 (EUR 18,174) ES: GBP 15,050 (EUR 19,565) |
PA: GBP 1070 (EUR 1391) compared to ES | NA | PA: 0.63 ES: 0.65 |
ES-PA: GBP 43,727.01 (EUR 56,845.12) |
| ST5 | Roblin et al., 2015 [40] | NA | RA: EUR 26,260,058.60 compared to ES | NA | NA | NA |
| ST6 | Velayos et al., 2013 [41] | RA: USD 31,870 (EUR 23,902.5) ES: USD 37,266 (EUR 27,949.5) |
RA: USD 5396 (EUR 4047) compared to ES | NA | RA: 0.80 ES: 0.80 |
ES-RA: Dominated by RA |
| ST7 | Wu et al., 2021 [42] | NA | PA: AUD 304,916.95 (EUR 196,394.48) compared to RA | NA | NA | NA |
| ST8 | Ganesnanthan et al., 2020 [43] | NA | PA: GBP 56,865 (EUR 62,551) compared to ES PA post-induction: GBP 51,595 (EUR 56,754.50) compared to ES RA: GBP 27,081.85 (EUR 29,790.04) compared to ES |
NA | NA | NA |
| ST9 | Guidi et al., 2018 [44] | RA: EUR 3,230,810.44 ES: EUR 3,788,285.67 |
RA: EUR 557,475.23 compared to ES | RA: EUR 39,197.38 compared to ES | NA | NA |
| ST10 | Taks et al., 2017 [45] | NA | PA: EUR 47,026 compared to RA | NA | NA | NA |
| ST11 | Vande Castelee et al., 2015 [46] | PA: EUR 5,201,473 ES: EUR 5,276,773 |
PA: EUR 75,300 compared to ES | PA: EUR 300 compared to ES | PA: 0.82 ES: 0.84 |
ES-PA: EUR 3,901,554.40 |
| ST12 | Steenholdt et al., 2015 [47] | RA: USD 22,066 (EUR 17,652.80) ES: USD 29,072 (EUR 23,257.60) |
RA: USD 7006 (EUR 5604.8) compared to ES | RA: EUR 111.11 compared to ES | NA | NA |
| ST13 | Steenholdt et al., 2014 [48] | RA: USD 26,164.67 (EUR 19,623.5) ES: USD 39,771.33 (EUR 29,828.5) |
RA: USD 13,606.67 (EUR 10,205) compared to ES | RA: EUR 233.92 compared to ES | NA | NA |
QALY: quality-adjusted life-years; ICER: incremental cost-effectiveness ratio; PA: proactive TDM; RA: reactive TDM; ES: empirical strategy; NA: not available; USD: United States Dollars; AUD: Australian dollars.